Adults with blood cancers who need a donor stem cell transplant now have a new defense against one of the procedure’s most debilitating complications. The FDA approved Tregzi on July 1, 2026, making it the first donor-derived regulatory T-cell therapy cleared to improve chronic graft-versus-host disease-free survival after allogeneic hematopoietic stem cell transplant. The approval, […]